Hill-Rom Holdings, Inc. (HRC) Director Purchases $24,990.00 in Stock

Hill-Rom Holdings, Inc. (NYSE:HRC) Director Mary Garrett purchased 300 shares of the business’s stock in a transaction dated Tuesday, December 5th. The stock was purchased at an average price of $83.30 per share, for a total transaction of $24,990.00. Following the completion of the acquisition, the director now owns 300 shares of the company’s stock, valued at $24,990. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Hill-Rom Holdings, Inc. (HRC) traded up $0.20 on Thursday, reaching $83.44. The company had a trading volume of 268,329 shares, compared to its average volume of 503,729. Hill-Rom Holdings, Inc. has a fifty-two week low of $54.59 and a fifty-two week high of $85.25. The company has a market capitalization of $5,474.99, a price-to-earnings ratio of 21.55, a PEG ratio of 1.77 and a beta of 1.19. The company has a quick ratio of 1.34, a current ratio of 1.77 and a debt-to-equity ratio of 1.55.

Hill-Rom (NYSE:HRC) last released its earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.05. Hill-Rom had a return on equity of 20.27% and a net margin of 4.87%. The business had revenue of $738.30 million for the quarter, compared to analyst estimates of $731.10 million. During the same quarter in the prior year, the company posted $1.18 earnings per share. Hill-Rom’s revenue was up 4.6% on a year-over-year basis. equities research analysts anticipate that Hill-Rom Holdings, Inc. will post 4.26 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 15th will be issued a dividend of $0.18 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.72 annualized dividend and a yield of 0.86%. Hill-Rom’s payout ratio is presently 36.18%.

A number of brokerages have recently commented on HRC. Zacks Investment Research upgraded Hill-Rom from a “sell” rating to a “hold” rating in a report on Monday, September 18th. ValuEngine lowered Hill-Rom from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Barclays boosted their price target on Hill-Rom from $86.00 to $90.00 and gave the company an “overweight” rating in a report on Monday, November 6th. Bank of America restated a “hold” rating on shares of Hill-Rom in a report on Wednesday, November 22nd. Finally, Stifel Nicolaus boosted their price target on Hill-Rom from $84.00 to $85.00 and gave the company a “buy” rating in a report on Monday, November 6th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Hill-Rom has a consensus rating of “Buy” and an average target price of $89.57.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HRC. Seven Eight Capital LP bought a new stake in Hill-Rom in the second quarter valued at approximately $127,000. Acrospire Investment Management LLC raised its stake in Hill-Rom by 43.4% in the second quarter. Acrospire Investment Management LLC now owns 1,983 shares of the medical technology company’s stock valued at $158,000 after buying an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Hill-Rom by 10.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock valued at $175,000 after buying an additional 204 shares during the period. Citigroup Inc. raised its stake in Hill-Rom by 21.1% in the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock valued at $198,000 after buying an additional 433 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its stake in Hill-Rom by 101.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock valued at $204,000 after buying an additional 1,367 shares during the period. Institutional investors and hedge funds own 82.35% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/12/07/hill-rom-holdings-inc-hrc-director-purchases-24990-00-in-stock.html.

About Hill-Rom

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Insider Buying and Selling by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply